Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy
2019 ASCO Annual Meeting
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas W. Flaig, MD, of the University of Colorado, discuss phase II findings on a novel predictive biomarker of response to the two accepted neoadjuvant regimens for muscle-invasive bladder cancer: methotrexate/vinblastine/doxorubicin/cisplatin and gemcitabine/cisplatin (Abstract 4506).
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, University of Paris-Sud, discusses study findings showing that not only does darolutamide prolong metastasis-free survival, it maintains quality of life as well as delays worsening of pain and disease-related symptoms compared with placebo for patients with nonmetastatic castrate-resistant prostate cancer (Abstract 5000).
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses findings from the phase III ICARIA-MM trial showing that isatuximab, pomalidomide, and low-dose dexamethasone significantly improved progression-free survival and overall response vs pomalidomide and dexamethasone (Abstract 8004).
Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings that showed, for adults with locally advanced cancer across five different disease sites, proton chemoradiotherapy was associated with significantly reduced acute adverse events, with no difference in disease-free or overall survival (Abstract 6521).
Margaret A. Tempero, MD, discusses phase III results from the multicenter APACT trial, which showed that adjuvant nab-paclitaxel plus gemcitabine may be an option for patients who are ineligible for treatment with FOLFIRINOX (Abstract 4000).
Jame Abraham, MD, of the Cleveland Clinic, provides commentary on the NALA study findings on neratinib plus capecitabine vs lapatinib plus capecitabine in patients previously treated with HER2-positive metastatic breast cancer (Abstract 1002).
